Creating long-term value requires focus, expertise and a commitment to transformation. At PAI, we follow a proven playbook designed to drive organic growth and deliver measurable results across our portfolio.

Corporate carve-outs and strategic partnerships are central to PAI’s investment approach, representing c. 40% of investments made to date. These opportunities require experience, trust and a clear vision for growth.

At PAI Partners, our commitment to investing in the real economy goes beyond strategy – it’s about delivering tangible impact, fostering resilient growth and creating lasting value.

The last 12 months have seen continued momentum at PAI. We’ve captured some of the highlights in this short video.

We recently sat down with members of the SGD Pharma and PAI teams to talk about how they are turning an ambitious plan into reality.

PAI recently completed the sale of ELITech Group, a global manufacturer of in-vitro diagnostics, to Bruker, a prominent international life science research and diagnostics solutions provider.